SCHEMBL3498385

SCHEMBL3498385

CCOC(=O)c1cn2cc(/C=C/c3ccccc3)ccc2n1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
POLB P06746 1/20 0.56
RAB9A P51151 6/20 0.52
NPC1 O15118 4/20 0.52
GAA P10253 1/20 0.51
GABRA2 P47869 4/20 0.49
GABRB2 P47870 4/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
MAPT P10636 2/20 0.47
ADORA3 P0DMS8 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
CYP1A2 P05177 1/20 0.46
TGFBR1 P36897 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498388 1.00 KDM4E (0.56) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL3498738 0.92 KDM4E (0.59) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL3498736 0.92 KDM4E (0.59) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL3500191 0.89 KDM4E (0.55) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL3500190 0.89 KDM4E (0.55) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL3499344 0.88 KDM4E (0.57) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL1638237 0.84 KDM4E (0.61) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL21033604 0.83 KDM4E (0.60) KDM4EPOLBRAB9ANPC1GAA
SCHEMBL3500264 0.83 PTGS1 (0.58) KDM4ERAB9ANPC1MAPTCYP1A2
SCHEMBL3500261 0.83 PTGS1 (0.58) KDM4ERAB9ANPC1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 KDM4E 2059/4885POLB 4658/4885RAB9A 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.